Across TCGA pan-cancer cohorts, IGHV3-16 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IGHV3-16 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGHV3-16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV3-16 expression acts as an unfavorable survival marker.

LUAD are the cancer types where IGHV3-16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.098	0.682	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: IGHV3-16 tumor-vs-normal RNA expression · all IGHV3-16 data types